Conversion of A3 adenosine receptor agonists into selective antagonists by modification of the 5′-ribofuran-uronamide moiety

被引:32
|
作者
Gao, ZG
Joshi, BV
Klutz, AM
Kim, SK
Lee, HW
Kim, HO
Jeong, LS
Jacobson, KA [1 ]
机构
[1] NIDDKD, Bioorgan Chem Lab, Mol Recognit Sect, NIH, Bethesda, MD 20892 USA
[2] Ewha Womans Univ, Coll Pharm, Med Chem Lab, Seoul 120750, South Korea
基金
美国国家卫生研究院;
关键词
nucleoside; G protein-coupled receptor; adenylyl cyclase; molecular modeling; radioligand binding;
D O I
10.1016/j.bmcl.2005.10.054
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The highly selective agonists of the A(3) adenosine receptor (AR), Cl-IB-MECA (2-chloro-N-6-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine), and its 4'-thio analogue, were successfully converted into selective antagonists simply by appending a second N-methyl group on the 5'-uronamide position. The 2-chloro-5'-(N,N-dimethyl)uronamido analogues bound to, but did not activate, the human A(3)AR, with K-i values of 29 nM (4'-O) and 15 nM (4'-S), showing > 100-fold selectivity over A(1), A(2A), and A(2B)ARs. Competitive antagonism was demonstrated by Schild analysis. The 2-(dimethylamino)-5'-(N,N-dimethyl)uronamido substitution also retained A3AR selectivity but lowered affinity. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:596 / 601
页数:6
相关论文
共 50 条
  • [21] Current Status in the Design and Development of Agonists and Antagonists of Adenosine A3 Receptor as Potential Therapeutic Agents
    Mailavaram, Raghu P.
    Al-Attraqchi, Omar H. A.
    Kar, Supratik
    Ghosh, Shinjita
    CURRENT PHARMACEUTICAL DESIGN, 2019, 25 (25) : 2772 - 2787
  • [22] Design of (N)-methanocarba adenosine 5′-uronamides as species-independent A3 receptor-selective agonists
    Melman, Artem
    Gao, Zhan-Guo
    Kumar, Deepmala
    Wan, Tina C.
    Gizewski, Elizabeth
    Auchampach, John A.
    Jacobson, Kenneth A.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (09) : 2813 - 2819
  • [23] Reply to 'Highly selective A3 adenosine receptor agonists relieve chronic neuropathic pain'
    Maia, Rodolfo Couto
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2017, 27 (08) : 969 - 969
  • [24] New substituted MECA derivatives as potent and selective agonists for the human adenosine A3 receptor
    Lambertucci, Catia
    Dal Ben, Diego
    Lammi, Carmen
    Marucci, Gabriella
    Ramadori, Anna Teresa
    Volpini, Rosaria
    Klotz, Karl-Norbert
    Cristalli, Gloria
    PURINERGIC SIGNALLING, 2010, 6 (01) : 91 - 91
  • [25] Synthesis of novel apio carbocyclic nucleoside analogues as selective A3 adenosine receptor agonists
    Lee, JA
    Moon, HR
    Kim, HO
    Kim, KR
    Lee, KM
    Kim, BT
    Hwang, KJ
    Chun, MW
    Jacobson, KA
    Jeong, LS
    JOURNAL OF ORGANIC CHEMISTRY, 2005, 70 (13): : 5006 - 5013
  • [26] A1 and A3 adenosine receptor agonists:: an overview
    Baraldi, PG
    Cacciari, B
    Romagnoli, R
    Spalluto, G
    EXPERT OPINION ON THERAPEUTIC PATENTS, 1999, 9 (05) : 515 - 527
  • [27] Anticancer activity study of A3 adenosine receptor agonists
    Marucci, Gabriella
    Santinelli, Claudia
    Buccioni, Michela
    Navia, Aleix Marti
    Lambertucci, Catia
    Zhurina, Anastasia
    Yli-Harja, Olli
    Volpini, Rosaria
    Kandhavelu, Meenakshisundaram
    LIFE SCIENCES, 2018, 205 : 155 - 163
  • [28] Pharmacological and therapeutic effects of A3 adenosine receptor agonists
    Fishman, Pnina
    Bar-Yehuda, Sara
    Liang, Bruce T.
    Jacobson, Kenneth A.
    DRUG DISCOVERY TODAY, 2012, 17 (7-8) : 359 - 366
  • [29] Highly potent and selective human adenosine A3 receptor antagonists: Triazoloquinazoline derivatives.
    Kim, YC
    Ji, XD
    Olah, ME
    Stiles, GL
    Jacobson, KA
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1997, 213 : 42 - MEDI
  • [30] New strategies for the synthesis of A3 adenosine receptor antagonists
    Baraldi, PG
    Bovero, A
    Fruttarolo, F
    Romagnoli, R
    Tabrizi, MA
    Preti, D
    Varani, K
    Borea, PA
    Moorman, AR
    BIOORGANIC & MEDICINAL CHEMISTRY, 2003, 11 (19) : 4161 - 4169